# Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th

> **NCT07655115** · PHASE3 · RECRUITING · sponsor: **Hospital General Universitario Gregorio Marañon** · enrollment: 103 (estimated)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Arbaclofen
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07655115
- **Lead sponsor:** Hospital General Universitario Gregorio Marañon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2026-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07655115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07655115, "Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07655115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*